December 16, 2022 7:52am

Following a rough week

Indications:  NONE

News: uniQure N.V. (QURE) announced that its partner, global biotechnology leader CSL (ASX: CSL), has received a positive opinion recommending conditional marketing authorization (CMA) for etranacogene dezaparvovec from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Etranacogene dezaparvovec is a one-time gene therapy for the treatment of appropriate adults with hemophilia B that reduces the rate of annual bleeds after a single infusion.1,2

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!


8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -1.03% or (-344 points), S&P futures are DOWN -1.04% or (-40 point) and NASDAQ futures are DOWN -0.66% or (-75 points) early in the pre-open – so far,

Stock futures were lower Friday morning,

European markets lower,

Asia-Pacific markets trade lower.



We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes fell sharply Thursday after new data showed retail sales fell more than expected in November, raising fears that the Fed’s interest rate hikes could be tipping the economy into a recession.

The Dow closed DOWN -764.13 points (-2.25%), the S&P closed DOWN -99.57 points (-2.49%) while the Nasdaq closed DOWN -360.36 points (-3.23%)

Economic Data Docket: December’s purchasing managers’ indexes within services and manufacturing.


Thursday’s (9/15) … RegMed Investors’ (RMi) closing bell: “cell and gene therapy sector bottoms. Where and what are the coming sector catalysts (?), coming off two (2) losing sessions; disappointing retail sales report suggest inflation is taking a toll on investors.” …


Ebb and flow:

Q4 – December – 7 negative and 4 positive closes

·         November -1 holiday, 14 negative and 8 positive closes

·         October -1 neutral, 11 positive and 9 negative closes

Q3/22 –

·         September – 1 holiday, 10 positive and 11 negative closes

·         August – 1 neutral, 11 positive and 11 negative closes

·         July - 1 holiday, 10 negative and 10 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Attention remained laser-focused on week’s busy economic calendar; there’s still a bit of hesitation in front of inflation data to really see the reality of the markets and cell and gene therapy sector ability or capacity to move upward.


The BOTTOM LINE: I try to keep it simple and short!

Today, the sector is about to experience a second-day reaction to Fed meetings, especially with so much in flux.

The past two days are a great example that it's not the news, it's the market's reaction to the news.

This market and sector aren't giving any reason to add exposure as the major indexes can't hold a gain

If you're buying on weakness, you might be jumping onto a sinking ship.

Be prepared … just 10 trading days remain in 2022.

Until December 31, investors may want to be cautious about making new buys.

I’d be calculating selling for tax purposes amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.

Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment,


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.